Publications by Keno Strotjohann

ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD/MASH

Johan Auwerx, Xiaoxu Li, Jia Liu, Qi Wang, Sandra Rodriguez Lopez, Keno Strotjohann

Background & Aims: Recent findings reveal the importance of tryptophan-initiated de novo nicotinamide adenine dinucleotide (NAD+) synthesis in the liver, a process previously considered secondary to biosynthesis from nicotinamide. The enzyme α-amino-β-carb ...

2025

Cyclo His-Pro Attenuates Muscle Degeneration in Murine Myopathy Models

Johan Auwerx, Xiaoxu Li, Alessia De Masi, Tanes Imamura de Lima, Keno Strotjohann

Among the inherited myopathies, a group of muscular disorders characterized by structural and metabolic impairments in skeletal muscle, Duchenne muscular dystrophy (DMD) stands out for its devastating progression. DMD pathogenesis is driven by the progress ...

Wiley2024

ACMSD INHIBITION REDUCES HEPATIC INFLAMMATION AND FIBROSIS IN A MURINE THERMONEUTRALITY MODEL OF NASH

Johan Auwerx, Krisztian Homicsko, Xiaoxu Li, Jia Liu, Sandra Rodriguez Lopez, Richardus Houtkooper, Maroun Bou Sleiman, Keno Strotjohann

Lippincott Williams & Wilkins2023

INHIBITING SARM1 IS MORE EFFICACIOUS THAN NICOTINAMIDE RIBOSIDE SUPPLEMENTATION FOR THE TREATMENT OF A MOUSE MODEL WITH NAFLD/NASH

Johan Auwerx, Krisztian Homicsko, Xiaoxu Li, Jia Liu, Sandra Rodriguez Lopez, Richardus Houtkooper, Maroun Bou Sleiman, Keno Strotjohann

Lippincott Williams & Wilkins2023